Press release
Non-alcoholic Steatohepatitis Market Development, Share, Strategies and Top Competitors Conatus Pharmaceuticals Inc, Galmed Pharmaceuticals Ltd, Gemphire, Genfit SA, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc
Non-alcoholic Steatohepatitis Market
Global non-alcoholic steatohepatitis market is set to witness healthy CAGR of 56.15% in the forecast period of 2019- 2026. The report contains data of the base year 2018 and historic year 2017. Increasing demand for NASH therapeutics and increasing presence of pipeline drugs are the factor for the growth.
Get Sample Copy of Global Non-alcoholic Steatohepatitis Market Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-non-alcoholic-steatohepatitis-market
Major Competitors Included:
ALLERGAN,
Zydus Cadila,
Conatus Pharmaceuticals Inc,
Galmed Pharmaceuticals Ltd,
Gemphire,
Genfit SA,
Gilead Sciences, Inc.,
Intercept Pharmaceuticals, Inc.,
Novartis AG,
Shire,
Enzo Biochem Inc.,
Novo Nordisk A/S,
Immuron,
Pfizer Inc.,
Algernon Pharmaceuticals,
Celerion,
NuSirt Biopharma,
Perspectum Diagnostics.,
Boehringer Ingelheim International GmbH and others.
Non-alcoholic Steatohepatitis Market Definition:
Nonalcoholic steatohepatitis (NASH) is a kind of a non-alcoholic fatty liver disease (NAFLD) which usually occurs when fat is collected in the liver. It usually causes inflammation and also damages the liver cell. NASH usually occurs on people who don’t consume alcohol. Itis very common in patients with conditions such as hypertension, type 2 diabetes, high blood lipid, heart disease, and others. NASH can also cause problems like liver cancer and cirrhosis. According to researchers, about 3 to 12 percentage of population in United States is suffering from nonalcoholic steatohepatitis.
Table of Contents:
Introduction
Market Segmentation
Market Overview
Executive Summary
Premium Insights
Global, By Component
Product Type
Delivery
Industry Type
Geography
Company Landscape
Company Profiles
Related Reports
View Detailed Table of Content @ https://www.databridgemarketresearch.com/toc/?dbmr=global-non-alcoholic-steatohepatitis-market
Non-alcoholic Steatohepatitis Market Drivers
Increasing cases of diabetes and obesity is driving the growth of the market
Growing Nonalcoholic steatohepatitis (NASH) affected population worldwide will also drive the market growth
Rising healthcare expenditure will also propel the market growth
Increasing launches of pipeline drugs will also contribute as a factor for the growth of this market
Non-alcoholic Steatohepatitis Market Restraints
Lack of proper diagnostic technologies for Nonalcoholic steatohepatitis (NASH) will restrain the market growth
Less demand in the underdeveloped countries is another factor restraining the market growth
Non-alcoholic Steatohepatitis Market : Segmentation
Non-alcoholic Steatohepatitis Market : By Drug Type
o Vitamin E & Pioglitazone
o Ocaliva
o Obeticholic acid
o Elafibranor
o Selonsertib & Cenicriviroc
o Others
Non-alcoholic Steatohepatitis Market: By Sales Channel
o Hospital Pharmacy
o Online Provider
o Retail Pharmacy
Non-alcoholic Steatohepatitis Market : By Disease Cause
o Hypertension
o Heart Disease
o High Blood Lipid
o Type 2 Diabetes
o Obesity
Non-alcoholic Steatohepatitis Market : By End User
o Hospitals
o Clinics
o Homecare settings
Non-alcoholic Steatohepatitis Market : By Geography
North America
Europe
Asia-Pacific
South America
Middle East and Africa
Key Developments in the Non-alcoholic Steatohepatitis Market:
In July 2019, Altimmune, Inc announced that they have acquired Spitfire Pharma, Inc along with their product candidate SP-1373 to treat non-alcoholic steatohepatitis (NASH). The main aim of the acquisition is to help the company to meet the requirement of the people for treatment of Nonalcoholic steatohepatitis (NASH). This acquisition will strengthen the company’s position in the market and will provide better treatment to their patients
In July 2019, InSphero AG launched their new 3D InSight Human Liver Disease Discovery Platform which is specially designed for the safety testing of nonalcoholic steatohepatitis drugs and nonalcoholic fatty liver disease. The main aim of this launch is to meet the increasing demand of research community for efficient and fast screening of the drug candidates
Non-alcoholic Steatohepatitis Market Competitive Analysis:
Global non-alcoholic steatohepatitis market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of non-alcoholic steatohepatitis market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Reasons to Purchase this Report
Current and future of global non-alcoholic steatohepatitis market outlook in the developed and emerging markets
The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
Regions/Countries that are expected to witness the fastest growth rates during the forecast period
The latest developments, market shares, and strategies that are employed by the major market players
Customization of the Report:
All segmentation provided above in this report is represented at country level
All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)
Inquire for customization in Report @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-non-alcoholic-steatohepatitis-market
Contact Us:
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email: Corporatesales@databridgemarketresearch.com
About Us:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Non-alcoholic Steatohepatitis Market Development, Share, Strategies and Top Competitors Conatus Pharmaceuticals Inc, Galmed Pharmaceuticals Ltd, Gemphire, Genfit SA, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc here
News-ID: 2079933 • Views: …
More Releases from Data Bridge Market Research
Water Treatment System Market: Sustaining the Future of Clean Water
Introduction
Understanding Water Treatment Systems
Water treatment systems are designed to purify and disinfect water for various uses-drinking, industrial processes, irrigation, and wastewater reuse. These systems eliminate contaminants such as bacteria, viruses, heavy metals, chemicals, and particulates, making water safe and sustainable for consumption and use.
Importance in Global Sustainability
Clean water is essential to life and industrial progress. With growing water demand and pollution, water treatment systems are now critical infrastructure across the…
Veterinary X-Ray Market Size, Analysis, Scope, Demand, Opportunities, Statistics
According to Data Bridge Market Research The global Veterinary X-Ray market size was valued at USD 915.19 million in 2024 and is projected to reach USD 1576.00 million by 2032, with a CAGR of 7.03 % during the forecast period of 2025 to 2032.
With increasing globalization and digital disruption, the Equine X-Ray Solutions Market is expanding across multiple industries, . Market research data indicates that businesses in the Companion Animal…
Veterinary X-Ray Market Size, Analysis, Scope, Demand, Opportunities, Statistics
According to Data Bridge Market Research The global Veterinary X-Ray market size was valued at USD 915.19 million in 2024 and is projected to reach USD 1576.00 million by 2032, with a CAGR of 7.03 % during the forecast period of 2025 to 2032.
With increasing globalization and digital disruption, the Equine X-Ray Solutions Market is expanding across multiple industries, . Market research data indicates that businesses in the Companion Animal…
Veterinary X-Ray Market Size, Analysis, Scope, Demand, Opportunities, Statistics
According to Data Bridge Market Research The global Veterinary X-Ray market size was valued at USD 915.19 million in 2024 and is projected to reach USD 1576.00 million by 2032, with a CAGR of 7.03 % during the forecast period of 2025 to 2032.
With increasing globalization and digital disruption, the Equine X-Ray Solutions Market is expanding across multiple industries, . Market research data indicates that businesses in the Companion Animal…
More Releases for Steatohepatitis
Nonalcoholic Steatohepatitis (NASH) Market Massive Growth opportunity Ahead
Introduction
Nonalcoholic Steatohepatitis (NASH) is an advanced form of nonalcoholic fatty liver disease (NAFLD) characterized by fat accumulation in the liver along with inflammation and liver cell damage. If left untreated, NASH can progress to fibrosis, cirrhosis, liver failure, or hepatocellular carcinoma. Closely tied to the global obesity and diabetes epidemic, NASH has become a major healthcare burden, with millions affected worldwide and no widely approved curative therapy to date.
The NASH…
Non-Alcoholic Steatohepatitis Treatment Market Size, Share
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Non-Alcoholic Steatohepatitis Treatment Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $2.67 billion In 2028…
Non-Alcoholic Steatohepatitis (NASH) - Drug Pipeline Landscape, 2023
Nonalcoholic steatohepatitis (NASH) is a type of fatty liver disease. It is characterized by the accumulation of fat in the liver, inflammation, and damage. NASH can lead to cirrhosis, liver failure, and death. The exact cause of NASH is unknown, but it is believed to be associated with obesity, insulin resistance, and diabetes. Treatment of NASH is focused on weight loss, exercise, and the control of diabetes and insulin resistance.
NASH…
Non Alcoholic Steatohepatitis (NASH) Market Size to Hit $21,879 Million by 2028 …
According to our experience research team, Non Alcoholic Steatohepatitis (NASH) Market was valued at USD 1,569 Million in 2021, and the global Non Alcoholic Steatohepatitis (NASH) industry is projected to reach a value of USD 21,879 Million by 2028, at a CAGR of 60.4% during the forecast period 2022-2028
The report is focused on gaining various Non Alcoholic Steatohepatitis (NASH) market trends, dynamics, growth drivers, opportunities, weaknesses, strengths, and threats restraining…
Nonalcoholic Steatohepatitis Treatment Market Analysis
As per the research conducted by GME, the Global Nonalcoholic Steatohepatitis Treatment Market will grow with a CAGR value of 39.1% by 2026. Over the forecast era, the production of NASH biomarkers is expected to be aided by increasing demand for non-invasive diagnostic tools and increased patient awareness. The low use of invasive procedures for disease diagnosis is due to the high cost of liver biopsy, its invasiveness, and patients'…
Emerging Opportunities in Nonalcoholic Steatohepatitis Therapeutics Market
Global Nonalcoholic Steatohepatitis (NASH) Market: Snapshot
Nonalcoholic Steatohepatitis (NASH), a syndrome found in non-alcoholic patients, causes damage to liver that is histologically akin to alcoholic hepatitis. NASH results from fat in the liver, along with inflammation. Symptoms in NASH usually do not show, but it can be severe and lead to cirrhosis, which is permanent damage to the liver.
Those suffering from obesity, dyslipidemia, and glucose intolerance are most likely…
